Page last updated: 2024-11-07

amotosalen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID159599
CHEMBL ID2110621
SCHEMBL ID599618
MeSH IDM0426831

Synonyms (19)

Synonym
3-(2-aminoethoxymethyl)-2,5,9-trimethylfuro[3,2-g]chromen-7-one
161262-29-9
unii-k1ldz0vbc0
amotosalen [inn]
7h-furo(3,2-g)(1)benzopyran-7-one, 3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-
3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-7h-furo(3,2-g)(1)benzopyran-7-one
amotosalen
k1ldz0vbc0 ,
amotosalen [who-dd]
3-((2-aminoethoxy)methyl)-2,5,9-trimethyl-7h-furo(3,2-g)chromen-7-one
SCHEMBL599618
CHEMBL2110621
FERWCFYKULABCE-UHFFFAOYSA-N
Q9150146
amotosalen free base
161262-29-9 (free base)
DTXSID70870075
3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7h-furo[3,2-g][1]benzopyran-7-one
AKOS040750488

Research Excerpts

Overview

Amorosalen is a light-activated, DNA-, RNA-crosslinking psoralen compound. It is used to neutralise pathogens in therapeutic plasma.

ExcerptReferenceRelevance
"Amotosalen-HCl-UVA (AI) is a process to inactivate pathogens in therapeutic plasma (FFP). "( Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept ™) over a 5-year period of extensive delivery.
Benamara, H; Bost, V; Boussoulade, F; Chabre, C; Chavarin, P; Cognasse, F; Fabrigli, P; Garraud, O; Legrand, D; Odent-Malaure, H, 2015
)
2.09
"Amotosalen is a light-activated, DNA-, RNA-crosslinking psoralen compound, which is used to neutralise pathogens."( Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
, 2003
)
2.48

Effects

ExcerptReferenceRelevance
"Amotosalen, a psoralen, has been utilized for photochemical treatment (PCT) of apheresis platelets (PLTs) and pooled buffy coat PLTs suspended in additive solution. "( Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
Awatefe, H; Carmichael, P; Lin, L; Moroff, G; Myrup, A; Skripchenko, A; Thompson-Montgomery, D; Wagner, SJ, 2009
)
2

Treatment

Amotosalen treatment of plasma and cryopreservation of platelets affect the quality and potentially the interplay between platelets and coagulation factors. Amotosalan-UVA treatment does not significantly alter the miRNA profile of platelet concentrates generated and stored using standard blood banking conditions.

ExcerptReferenceRelevance
"Amotosalen treatment of plasma and cryopreservation of platelets affect the quality and potentially the interplay between platelets and coagulation factors. "( Cryopreserved platelets and amotosalen-treated plasma in an experimental clot formation set-up.
Ehn, K; Larsson, L; Sandgren, P; Uhlin, M; Wikman, A, 2023
)
2.65
"Amotosalen-UVA treatment does not significantly alter the miRNA profile of platelet concentrates generated and stored using standard blood banking conditions."( Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
Arnason, NA; Gudmundsson, S; Hardarsson, B; Irsch, J; Johannson, F; Landrö, R; Rolfsson, O; Sigurjonsson, OE, 2019
)
2.25
"Amotosalen and UVA light treatment of MERS-CoV-spiked platelet concentrates efficiently and completely inactivated MERS-CoV infectivity (>4 logs), suggesting that such treatment could minimise the risk of transfusion-related MERS-CoV transmission."( Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates.
Abunada, Q; Alsaadi, MA; Azhar, EI; Damanhouri, GA; El-Kafrawy, SA; Hashem, AM; Hassan, AM; Hindawi, SI; Picard-Maureau, M; Tolah, AM, 2019
)
3.4
"Amotosalen/UVA light treatment of SARS-CoV-2 spiked human plasma units efficiently and completely inactivated >3·32 ± 0·2 log of SARS-CoV-2 infectivity, showing that such treatment could minimize the risk of transfusion-related SARS-CoV-2 transmission."( Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma.
Alandijany, TA; Azhar, EI; Bajrai, LH; Damanhouri, GA; El-Kafrawy, SA; Hassan, AM; Hindawi, SI; Tolah, AM, 2021
)
3.51
"The amotosalen/UVA-treated PCs confirmed previously published results with a slight increase of PSLs compared to untreated PCs. "( In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
Abonnenc, M; Aliotta, A; Crettaz, D; Lion, N; Prudent, M; Sonego, G; Tissot, JD, 2015
)
0.98
"Amotosalen/UVA light-treated FFP and PF24 were thawed after approximately 3 to more than 12 months of frozen storage and held at 1 to 6"( Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6
Benjamin, RJ; Corash, L; David, T; Erickson, A; Huang, N; Mufti, N; Rico, S; Waldhaus, K, 2017
)
2.22
"Amotosalen/UVA light-treated FFP and PF24 demonstrated retention of procoagulant and antithrombotic activity after 5 days post-thaw storage at 1 to 6"( Plasma treated with amotosalen and ultraviolet A light retains activity for hemostasis after 5 days post-thaw storage at 1 to 6
Benjamin, RJ; Corash, L; David, T; Erickson, A; Huang, N; Mufti, N; Rico, S; Waldhaus, K, 2017
)
2.22
"Amotosalen/UVA-treated platelet concentrates (PCs) have demonstrated efficacy for treating and preventing bleeding in clinical trials and in routine use; however, most studies were performed in haematology/oncology patients. "( Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
Amato, M; Astl, M; Benjamin, RJ; Chen, CY; Corash, L; Lin, JS; Nussbaumer, W; Schennach, H, 2017
)
2.22
"Amotosalen-treated, MCMV tetramer-positive memory (CD44(high)) CD8(+) T cells persisted to day +100 following infusion, and expressed IFN-gamma when presented with viral peptide."( Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
Alexander, SA; Gorechlad, JW; Hearst, JE; Hillyer, CD; Hossain, MS; Jaye, DL; Lezhava, L; Mittelstaedt, S; Roback, JD; Talib, S; Waller, EK, 2003
)
1.32
"Amotosalen-treated donor T cells, reisolated from BMT recipients' spleens >/=4 months after transplantation, proliferated in vitro, thus indicating repair of amotosalen-mediated DNA cross-links."( Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
Hillyer, CD; Hossain, MS; Lezhava, L; Roback, JD; Waller, EK, 2005
)
2.49

Toxicity

ExcerptReferenceRelevance
" Number, frequency, and dose of PLT transfusions; acute transfusion reactions; and adverse events were similar between the two groups."( Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Beris, P; Cazenave, JP; Conlan, MG; Flament, J; Hastka, J; Janetzko, K; Kientz, D; Klüter, H; Lin, JS; Lin, L; Lioure, B; Marblie, S; Mayaudon, V; Michel, M, 2005
)
0.33
"PCT PLTs provide effective and safe transfusion support for thrombocytopenic patients."( Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Beris, P; Cazenave, JP; Conlan, MG; Flament, J; Hastka, J; Janetzko, K; Kientz, D; Klüter, H; Lin, JS; Lin, L; Lioure, B; Marblie, S; Mayaudon, V; Michel, M, 2005
)
0.33
"To further assess the safety of PCT PLTs, the adverse event (AE) profile of PCT PLTs transfused in the SPRINT trial is reported."( Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Conlan, MG; Corash, L; Lin, JS; Lopez-Plaza, I; McCullough, J; Slichter, SJ; Snyder, E; Strauss, RG, 2005
)
0.57
" When tested up to toxic dose levels, S-59 was negative in the mouse bone marrow micronucleus assay and the rat hepatocyte unscheduled DNA synthesis (UDS) test."( The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment.
Gatehouse, D; Kirkland, D; Speit, G; Tice, RR, 2007
)
0.58
"An active haemovigilance programme was implemented to survey adverse events (AE) associated with transfusion of platelets photochemically treated with amotosalen and ultraviolet A (PCT-PLT)."( An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
Arroyo, JL; Barbolla, L; Cazenave, JP; Corash, L; Corral, M; De Meuter, R; Defoin, L; Dehenau, D; Fabrigli, P; Garraud, O; Gouezec, H; Hidajat, M; Jacquet, M; Kandel, G; Lambermont, M; Lin, L; Mendel, I; Osselaer, JC; Padrón, F; Raidot, JP; Sundin, D; Tardivel, R; Waller, C, 2008
)
0.76
" A series of clinical studies has shown PCT PLTs and PCT plasma to be safe and effective for transfusion in adults and pediatric patients."( Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino, V; Corash, L; Hanover, J; Lin, L; Sullivan, T, 2009
)
0.58
" An ATR was defined as an adverse event (AE) possibly related, probably related, or related to the PCT-plasma transfusion."( An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
Cazenave, JP; Corash, L; Defoin, L; Jacquet, M; Kientz, D; Lin, L; Liu, W; Mendel, I; Messe, N; Osselaer, JC; Propst, M; Sundin, D; Waller, C, 2010
)
0.57
" Secondary endpoints included 1- and 24-h count increment (CI), 24-h CCI, time to next PC transfusion, red blood cell (RBC) use, bleeding and adverse events."( A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Cid, J; Corash, L; Docherty, A; Knutson, F; Lin, L; Löf, H; Lozano, M; Maymó, RM; Pelly, J; Propst, M; Prowse, C; Roddie, H; Sherman, C; Tardivel, R, 2011
)
0.59
" aeruginosa microsyringe is an efficient and safe tool for in vivo antigen delivery."( A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.
Ahmadi, M; Aspord, C; Broisat, A; Chauchet, X; Cretin, F; Genestet, C; Ghezzi, C; Laurin, D; Le Gouëllec, A; Martin, S; Plumas, J; Polack, B; Toussaint, B; Trocme, C; Verove, J; Wang, Y, 2013
)
0.39
" untreated control platelet components, on three factors recently reported to be associated with serious adverse events associated with platelet component (PC) transfusions: sCD40L, IL-27 and sOX40 ligand."( Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
Cognasse, F; Garraud, O; Hamzeh-Cognasse, H; Laradi, S; Osselaer, JC, 2015
)
1.86
" The frequencies of transfusion-related adverse events (AE) were comparable (1·3% vs."( Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
Amato, M; Astl, M; Benjamin, RJ; Chen, CY; Lin, JS; Nussbaumer, W; Schennach, H, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
" Regarding blood gas and metabolic analysis, the most evident effect of PRT was an elevated glycolytic flux combined with higher acidity due to increased lactate accumulation."( Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
Gathof, BS; Oustianskaia, L; Picker, SM; Schneider, V, 2009
)
0.56

Dosage Studied

ExcerptRelevanceReference
" In a parallel model of active infection with free virus, human PLT in 35 percent autologous plasma and 65 percent PAS were dosed with 1 x 10(5) and 1 x 10(6) PFUs of MCMV."( Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model.
Hillyer, CD; Hillyer, WM; Jordan, CT; Lezhava, LJ; Maiers, TT; Newman, JL; Roback, JD; Saakadze, N, 2004
)
0.57
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (178)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.12)18.2507
2000's68 (38.20)29.6817
2010's82 (46.07)24.3611
2020's26 (14.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.69 (24.57)
Research Supply Index5.29 (2.92)
Research Growth Index6.12 (4.65)
Search Engine Demand Index50.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (10.06%)5.53%
Reviews30 (16.76%)6.00%
Case Studies2 (1.12%)4.05%
Observational1 (0.56%)0.25%
Other128 (71.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]